Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585231220232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Kerstin Hellwig und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neurological Clinic, University of Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Premature Birth, Abortion, Spontaneous. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Biogen.
Abstract (Originalsprache)
Background
Dimethyl fumarate (DMF) has a favorable benefit–risk profile treating people with multiple sclerosis and should be used in pregnant women only if the potential benefits outweigh potential risks to the fetus.
Objective
Assess pregnancy outcomes in a completed international registry (TecGistry) of women with MS exposed to DMF.
Methods
TecGistry included pregnant women with MS exposed to DMF, with data collected at enrollment, 6–7 months gestation, 4 weeks after estimated due date, and at postpartum weeks 4, 12, and 52. Outcomes included live births, gestational size, pregnancy loss, ectopic/molar pregnancies, birth defects, and infant/maternal death.
Results
Of 397 enrolled, median (range) age was 32 years (19–43). Median (range) gestational week at enrollment was 10 (0–39) and at first DMF exposure was 1 (0–13). Median (range) duration of gestational DMF exposure was 5 weeks (0–40). Fifteen (3.8%) spontaneous abortions occurred. Of 360 (89.1%) live births, 323 were full term and 37 were premature. One neonatal death and no maternal deaths occurred. Adjudicator-confirmed EUROCAT birth defects were found in 2.2%.
Conclusion
DMF exposure during pregnancy did not adversely affect pregnancy outcomes; birth defects, preterm birth, and spontaneous abortion were in line with rates from the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurological Clinic, University of Bochum, Bochum, Germany.
- Manchester Centre for Clinical Neurosciences, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Salford, UK.
- Department of Neurology, University College Dublin and St. Vincent's University Hospital, Dublin, Ireland.
- The Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Adult Neurology Clinic, Charlottesville, VA, USA.
- Biogen, Cambridge, MA, USA.
ORCID-Profile: Maria K Houtchens, Nicholas Everage
Förderung
- Biogen
Zitieren
APA
Hellwig, K., Rog, D., McGuigan, C., Houtchens, M. K., Bruen, D. R., Mokliatchouk, O., Branco, F., Levin, S., Everage, N., & Lin, X. (2024). Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585231220232
Vancouver
Hellwig K, Rog D, McGuigan C, Houtchens MK, Bruen DR, Mokliatchouk O, et al. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585231220232
BibTeX
@article{Hellwig2024,
author = {Hellwig, Kerstin and Rog, David and McGuigan, Christopher and Houtchens, Maria K and Bruen, Denise R and Mokliatchouk, Oksana and Branco, Filipe and Levin, Seth and Everage, Nicholas and Lin, Xiaochen},
title = {Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585231220232}
}
EUVIMED